Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cryptococcal pneumonia is identified as a fungal infection of the lungs, with and as the most common culprits. primarily affects immunocompromised individuals while infections occur mostly in immunocompetent hosts. We present a 76-year-old male on ibrutinib due to a history of chronic lymphocytic leukemia who had multiple hospitalizations for pneumonia and was later diagnosed with cryptococcal pneumonia through positive bronchoalveolar lavage fungal culture and lymph node biopsy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681705 | PMC |
| http://dx.doi.org/10.7759/cureus.47884 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The treatment of amphotericin B-resistant C neoformans meningitis: A case report and literature review.
Medicine (Baltimore)
August 2025
Department of Orthopedics, Xiangtan Central Hospital, Xiangtan, Hunan Province, China.
Rationale: Cryptococcal meningitis is caused by Cryptococcus neoformans and Cryptococcus gattii, predominantly affects immunocompromised host. Resistance to amphotericin B poses therapeutic challenges, especially in immunocompetent individuals, where evidence is scarce.
Patient Concerns: This study reports a case of an old immunocompetent male diagnosed with amphotericin B-resistant C neoformans meningitis.
The outcomes of cryptococcal disease in HIV-positive individuals following COVID-19 infection: A systematic review and meta-analysis.
J Infect Public Health
October 2025
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Jeddah, Saudi Arabia; King Abdullah International Medical Research Center, Jeddah 22384, Saudi Arabia.
Background: Cryptococcal disease is considered a major cause of morbidity in individuals with HIV in resource-limited settings. The long-term effects of COVID-19 and cryptococcal coinfection among people living with HIV (PLWHIV) have not been thoroughly investigated. This study examined the incidence of cryptococcosis among HIV-positive individuals following COVID-19.
View Article and Find Full Text PDFEpidemiology of tuberculosis and HIV coinfection among inpatients in chengdu, china, 2018-2022.
BMC Infect Dis
August 2025
Department of Tuberculosis, Public Health Clinical Center of Chengdu, 377 Jingming Rd, Chengdu City, 610000, China.
Background: Tuberculosis (TB) and human immunodeficiency virus (HIV) infection are infectious diseases that pose serious threats to human health. TB and HIV can interact to promote the progression of diseases. This study aims to provide basic evidence for the formulation of disease prevention and control strategies.
View Article and Find Full Text PDFDiagnostic performance of metagenomics sequencing for pulmonary fungal infections: a clinical evaluation using the Nanopore platform.
J Thorac Dis
July 2025
Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Pulmonary fungal infections are becoming increasingly prevalent, particularly among immunocompromised patients. Traditional culture-based and serological diagnostic methods exhibit low sensitivity and prolonged turnaround times (TATs), highlighting the need for more efficient diagnostic approaches. This study aims to evaluate the diagnostic performance of metagenomic third-generation sequencing (mTGS) using the Oxford Nanopore platform (Oxford Nanopore Technologies) for the detection of fungal pathogens in lower respiratory tract infections, and to compare its effectiveness with conventional diagnostic methods.
View Article and Find Full Text PDFInfective pneumonia following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: A real-world disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
PLoS One
August 2025
Department of Gastroenterology, the Affiliated Hospital of Southwest Medical University, Luzhou, China.
Background: Patients with inflammatory bowel disease may develop infective pneumonia after using tumor necrosis factor-α inhibitors(TNFis). Due to the limitations of clinical trials, the occurrence of infective pneumonia in patients with inflammatory bowel disease using tumor necrosis factor-α(TNF-α) inhibitors remains uncertain. This article primarily explores the relationship between TNF-α inhibitors and adverse events(AEs) related to infective pneumonia in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.
View Article and Find Full Text PDF